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Immunotherapy is a powerful and targeted cancer treatment that exploits the body's immune system to
attack and eliminate cancerous cells. This form of therapy presents the possibility of long-term control and
prevention of recurrence due to the memory capabilities of the immune system. Various immunotherapies
are successful in treating haematological malignancies and have dramatically improved outcomes in
melanoma. However, tackling other solid tumours is more challenging, mostly because of the
immunosuppressive tumour microenvironment (TME). Current in vitro models based on traditional 2D cell
monolayers and animal models, such as patient-derived xenografts, have limitations in their ability to mimic
the complexity of the human TME. As a result, they have inadequate translational value and can be poorly
predictive of clinical outcome. Thus, there is a need for robust in vitro preclinical tools that more faithfully
recapitulate human solid tumours to test novel immunotherapies. Microfluidics and lab-on-a-chip
technologies offer opportunities, especially when performing mechanistic studies, to understand the role
of the TME in immunotherapy, and to expand the experimental throughput when using patient-derived
tissue through its miniaturization capabilities. This review first introduces the basic concepts of
immunotherapy, presents the current preclinical approaches used in immuno-oncology for solid tumours
and then discusses the underlying challenges. We provide a rationale for using microfluidic-based
approaches, highlighting the most recent microfluidic technologies and methodologies that have been
used for studying cancer–immune cell interactions and testing the efficacy of immunotherapies in solid
tumours. Ultimately, we discuss achievements and limitations of the technology, commenting on potential
directions for incorporating microfluidic technologies in future immunotherapy studies.
1. Introduction
Immuno-oncology (I/O) is defined as the study and development
of therapies that exploit the immune system to fight cancer.1
Immunotherapy has the potential to harness the intrinsic
capabilities of the innate and adaptive immune system to
identify, target and eradicate cancer cells regardless of the tissue
they affect. In contrast to conventional anti-cancer therapies,
which do not distinguish between healthy and cancerous cells,
immunotherapy can sometimes offer specific cancer cell killing
and prevention against recurrence due to the memory
capabilities of the immune system.2 However, only a fraction of
cancer patients benefit from the current repertoire of
immunotherapies.3 As a result, researchers are left with the
challenge of enhancing the effectiveness of existing
immunotherapies, identifying predictive markers, and
discovering new immune pathways for intervention. For these
endeavours to succeed, better preclinical model systems that can
guide personalized immunotherapy treatments are required.
Solid tumours and their microenvironment, including
hypoxic conditions, acidic pH, nutrient starvation,
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dysfunctional vasculature and the occurrence of
immunosuppressive mechanisms, present significant
challenges for immune cells. Microfluidic technologies can
recapitulate many of these environmental features, offering
a versatile tool to study solid tumour immunotherapy and
representing valuable pre-clinical modelling systems.4 By
allowing greater control of fluid volumes, culture
conditions, surface chemistry and stimuli exposure, the
unique characteristics of the technology make
microfluidics an ideal platform for the development and
testing of immunotherapeutic agents.5–7 Microfluidic
technologies are often used to test anti-cancer therapies
on liquid,8,9 and solid tumours, such as spheroids,
organoids10 and tumour tissue slices.11 They are also used
to study immune cell behaviour, interaction and migration
in a reconstructed tumour model, but have not been
extensively used for efficacy studies of cancer
immunotherapy. Thus, microfluidic technologies offer an
underutilized resource for I/O.
In this review, we discuss the achievements to date made
by using microfluidic platforms for I/O investigations that
could not have been achieved in vivo or with standard in vitro
off-chip techniques. We first present an overview of the
present immunotherapeutic strategies for treating solid
tumours and their clinical limitations. Finally, we present an
outlook on future opportunities and challenges for
microfluidics in the I/O field that could impact the
progression of immunotherapy research.
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2. Immunotherapies for solid tumours
Common immunotherapeutic approaches (Fig. 1) and their
mode of action are described here briefly, directing the
reader to field-specific reviews, prior to discussing their
implementation for I/O in solid tumours using microfluidic
technologies.
Immune checkpoint inhibitors (ICIs) are the most successful
type of cancer immunotherapy to date. Immune checkpoint
molecules (or co-inhibitory molecules as they are also called)
are an inherent, natural system to regulate the magnitude of
immune response.12 ICIs prevent the interaction between
checkpoint molecules expressed on T cells and their ligands
expressed on antigen-presenting cells or cancer cells. This
inhibition unleashes greater T cell killing of cancer cells. Two
of the most well-studied checkpoint molecules include
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and
programmed cell death protein 1 (PD-1).13 Ipilimumab,
which targets CTLA-4, was the first ICI licensed for use in
cancer patients, in the treatment of metastatic melanoma.14
The first two PD-1 ICIs to be approved were pembrolizumab
and nivolumab, which show similar efficacy and
longstanding results as ipilimumab. These drugs are effective
in more than 25 types of solid cancers and multiple liquid
malignancies.14,15 However, response rates to anti-CTLA-4
and anti-PD-1 therapies vary by cancer type with upper limits
reaching only 40% in melanoma and lung cancer. Further
improvements to ICIs could benefit a great number of cancer
patients.
Adoptive cell transfer (ACT) therapy involves the
administration of immune cells to a patient. These cells can
be allogeneic (taken from a donor) or autologous cells (taken
from the patients' own immune cells) that have been isolated
and subsequently modified and expanded ex vivo, before
being returned to the patient.16,17 ACT products include
tumour-infiltrating T cells, T cell receptor (TCR)-transduced T
cells, chimeric antigen receptor (CAR)-T cells, NK cells and
CAR-NK cells. Thus far, ACT products have had success in
treating melanoma, head & neck cancer, renal cell carcinoma,
gynaecological cancers as well as leukaemia and
lymphomas.14 NK cell-based immunotherapy has been mostly
investigated for haematological malignancies, such as acute
myeloid leukemia (AML) and acute lymphoblastic leukaemia
(ALL). It has shown limited success in multiple solid
malignancies due to a lack of tumour infiltration and
proliferation.14 In addition to the immunosuppressive
tumour microenvironment limiting immune cell infiltration,
acquired mutations by cancer cells may provide additional
escape mechanisms to prevent T cell and NK cell attack.18
CAR-T cells are engineered to express a receptor specific to
an antigen on the surface of cancer cells, such as CD19.
These cells are used in leukemia and lymphoma patients,17
and they can stay active for up to a decade once injected,
potentially being a one-time therapy.13 Tisagenlecleucel and
axicabtagene-ciloleucel were the first to be approved for all
and certain types of large B-cell lymphoma.15 For solid
tumours, CAR-T cells are still being trialled in such cancers
as lung, brain, breast, pancreatic, sarcoma and metastatic
Fig. 1 Immunotherapy strategies. Schematic drawing of the most common immunotherapeutic methods and their mechanism of action (dendritic
cells (DC), adoptive cell transfer, (ACT)).
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colon cancer.14 However, a lack of suitable cancer-specific
antigens is a major limitation in the CAR-T cell field.3,15
Other challenges for CAR-T therapy include the laborious,
expensive and time-consuming production.13 In solid
tumours, CAR-T can be ineffective and fail to persist;
although, there are examples of progress in this area, such as
CAR-T cells targeting EGFR-expressing glioblastoma.13
Therapeutic vaccines consist of recombinant viral, bacterial
and yeast vectors, immunogenic peptides, immune cells or
killed tumour cells, which are used to improve immune
system activation against cancer cells.13,19–22 Cancer vaccines
stimulate dendritic cell function resulting in greater T cell
responses. This said, there has been little clinical success for
cancer vaccines thus far when administered alone. However,
promising results have been obtained when used in
combination with checkpoint inhibition.14 The Bacillus
Calmette–Guérin (BCG) vaccine is a nonspecific immune
stimulant that was the first immunotherapy to receive FDA
approval in 1990 to treat bladder cancer and remains the sole
intravesical agent to prevent non-muscle invasive bladder
cancer (NMIBC) progression.23 Neoantigen vaccines have
shown anti-tumour benefit for melanoma and glioblastoma,
whilst the TG01 mutant K-Ras peptide vaccine has been
approved for pancreatic cancer.14 Dendritic cell vaccines are
the most investigated vaccine type with sipuleucel-T approved
in 2010 for improving the overall survival in prostate cancer
patients, despite its complex production and moderate
efficacy.13,19 Thus, there is room for great improvement in
cancer vaccine technology.
Another type of immunotherapy involves oncolytic viruses,
which use the innate ability of a virus to kill cancer cells with
the potential to initiate an anti-tumour response. Oncolytic
viruses reproduce inside and destroy cancer cells, whilst
leaving normal cells unharmed and triggering the recognition
of antigens released from the lysed cancer cells that induces
further anti-tumour immune responses.14 Oncolytic viruses
can be beneficial in treating melanoma and brain cancer.15,18
With regard to solid tumours, intratumoural injection are
ideal for direct cancer cell lysis without detrimental systemic
effects or hepatic virus degradation.18 Unfortunately, this
procedure is not technically possible for most metastatic
cancers. Roadblocks for this form of therapy, in addition to
those caused by the tumour microenvironment (TME) and in
particular the dense fibrotic tissue surrounding tumours,
include complete viral clearance, and acquired specific
immunity against the virus, meaning that repeat therapy is
not possible.14,18
To stimulate anti-tumour immunity in cancer patients,
cytokine therapy may be employed. Cytokines, such as
interferons, interleukins, and granulocyte-macrophage colony-
stimulating factor (GM-CSF), can boost T cell responses,
activate apoptosis programs in cancer cells, delay angiogenesis,
stimulate dendritic cell maturation, and slow cancer
progression.13,18,24 A disadvantage to the use of cytokines,
however, is their short half-life. This means that treatment
needs to be delivered at a high dose, which can result in
serious side effects, such as cytokine release syndrome (CRS),
vascular leak syndrome and autoimmune attacks.13
For many immunotherapies to be successful,
immunosuppression must be overcome and anti-tumour
immunity must be engaged. This may be accomplished by
targeting immunosuppressive enzymes, such as indoleamine-
2,3-dioxygenase (IDO1) and arginase.25 The STING pathway,
which is a cytoplasmic DNA-sensing system (either self DNA
or non-self DNA such as viral DNA), represents another area
of active research for immunotherapy, because it activates
anti-cancer immune responses. The STING agonist, ADU-
S100, benefits patients with triple negative breast cancer and
melanoma when given in combination with spartalizumab, a
checkpoint inhibitor.26
Targeting solid tumours with immunotherapies is a field
in development. Many 2D and 3D in vitro models have been
established to investigate the effects of therapeutic agents,27
with reports of immune cells being unable to kill cancer cells
in a 3D environment, despite doing so in 2D assays,28 or with
anti-tumour effects of T cells being significantly reduced in
3D cultures.29 The complexity originating from the intricate
spatial cellular organizations within the TME and their
interactions with immune inhibitory mechanisms highlights
the need for complex in vitro models that faithfully mimic
human in vivo scenarios.30,31 Various solutions to these
challenges can be provided by microfluidic and organ-on-a-
chip technologies that enable miniaturisation, maximise the
use of intact human tumour tissue, allow the robust and
controlled modelling of tumour microenvironment
characteristics and facilitate the culture of multiple cell types
in defined spatial and temporal configurations.27 The
application of these technologies in the field of immune-
oncology is discussed in more detail below.
3. Microfluidics for solid tumour
immunotherapies
Microfluidic systems provide a cost-effective and sample-
efficient platform that enables complex in vitro models to be
formed and easily studied with a variety of microscopy
techniques. This is achieved more easily than for in vivo
models, because they allow manipulation of specific
experimental variables for mechanistic studies.32,27 Whilst
the technology has been used to develop I/O assays for liquid
tumours,6 its use in studying solid tumours has been less
frequent.7,29 The approaches used to date have been grouped
below according to their application in immune-oncology.
Cell interaction and migration studies
Several studies have focussed on investigating the
interactions between cancer and immune cells (Table 1).
Mattei et al. developed a microfluidic device to study the
role of the IRF-8 transcription factor in cross-talk between
murine melanoma and immune cells and the release of
soluble factors resulting in immune cell infiltration.36 The
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Table 1 Summary of microfluidic publications concerning cell interaction/migration studies in I/O. Legend: Ab: antibody, BCG: Bacillus Calmette–
Guérin, CAR-T: chimeric antigen receptor T cells, DC: dendritic cell, FPR1: frizzled-related protein, EMT: epithelial–mesenchymal transition, ICB: immune
checkpoint blockade, IT: immunotherapy, NK: natural killer cells, NP: nanoparticle, PBMC: peripheral blood mononuclear cells, PDMS:
polydimethylsiloxane, TCR: T cell receptor
Author Topic IT type Model
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Table 1 (continued)
Author Topic IT type Model
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device was composed of an enclosed central microfluidic
chamber with externally accessible compartments on either
side for culturing adherent B16.F10 murine melanoma cells
and non-adherent splenocytes from wild type (WT) and IRF-
8 KO mice. Compartments were connected by an array of
microchannels that permitted chemical and physical contact
amongst the two cell types. It was observed that tumour
cells were more invasive when cultured in vitro alongside
IRF-8 KO splenocytes rather than WT splenocytes.
Consistently with in vivo findings, this suggests IRF-8
inhibits tumour cell invasion. A previous study by Businaro
et al. also revealed, through FACS analysis, an upregulation
of CD69, a marker for activation, for WT splenocytes.34
Further investigating the interaction between WT/IRF-8 KO
immune cells and murine B16.F10 melanoma cells, Agliari
et al. created mathematical models and performed data
analysis on the dynamic movement of the splenocytes.35
More recently, Biselli et al. utilised the same platform to
study interactions between doxorubicin treated human
breast (MDA-MB-231) and colon cancer cells (patient derived
and HCT116 cell line) and human PBMC (from healthy
donors) expressing different genetic variants of the FPR1
gene, known to influence the response of phagocytic cells
(Fig. 2B).41 PBMCs sensed the chemo-attract signals from
chemotherapy-treated tumour cells and the device provided
the ability to record leukocyte migration towards target
tumour cells using time-lapse imaging, revealing that wild
type PBMCs moved towards tumour cells, whereas mutant
variants did not show target engagement. These results
mimicked clinical outcomes where patients who were
Table 1 (continued)
Author Topic IT type Model
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mutant carriers had a poorer prognosis. Other research
looked at the role of the FPR1 gene using a microfluidic
device where immune cell migration towards and
interaction with chemotherapy treated cancer cells could be
recorded.40 This model was subsequently modified to study
PBMC recruitment towards ECM-embedded (Matrigel)
cancer cells exposed to decitabine (DAC) and/or IFN.42
Greater infiltration of PBMC was reported toward tumour
cells treated with both DAC and IFN in comparison to one
agent alone and to untreated cells.
Bai et al. developed a multi-channel setup where human
umbilical vein endothelial cells (HUVEC) were co-cultured
with hydrogel-embedded tumour aggregates and
macrophages.37 The effect of different macrophage subtypes
on tumour aggregate dispersion was studied to mimic
epithelial–mesenchymal transition (EMT), inducing cancer
cell dissociation via CD11b and ICAM-1 interaction. The
study showed ICAM-1 involvement in the dissociation and
migration of tumour cell aggregates. The use of
microfluidics in this application allowed real-time
monitoring and precise measurements of cell–cell distances.
Subsequently, Chen et al. studied the role of neutrophils in
promoting cancer cell metastasis under perfusion
conditions in order to assess their potential as targets for
cancer immunotherapies (Fig. 2F).43 The device used
allowed the formation of eight independent vascular beds
with a single gel injection port connected by a branching
network. Tumour cells proximal to neutrophils showed
significantly higher extravasation, suggesting that close
neutrophil association is a determining factor for tumour
cell extravasation. More recently, a microfluidic device was
proposed to study the migration and development of
various subsets of monocytes and macrophages as targets
for anti-metastatic immunotherapies and their effect on
cancer cell extravasation (Fig. 2D).44
Other work in this field includes the development of
microfluidic assays to study interactions between human lung
cancer cells, macrophages and myofibroblasts (Fig. 2C).33 A
Y-shaped channel connected three chambers and was designed
so all angles were at 120° to allow for symmetrical distribution
of conditioned media. The work showed that TNF can
simultaneously promote cancer cell migration while also
limiting the migration-promoting abilities of myofibroblasts,
but did not study the role of anti-TNF antibodies in the context
of cancer immunotherapy.
A microfluidic co-culture chip, consisting of an ECM filled
channel (Matrigel) and seven migration channels between
culture chambers, was created to study the role of lactate on
macrophage recruitment and cytotoxicity against cancer cells,
which has relevance to BCG immunotherapy.38 This was the
Fig. 2 Microfluidic assays for studying cancer and immune cell migration and interactions. (A) Adapted with permission from Liu et al., 2015,
Copyright 2015, Oncotarget.39 (B) Adapted with permission from Biselli et al., Scientific Reports, 2017 http://creativecommons.org/licenses/by/4.0/.
(C) Adapted with permission from Hsu et al., 2012, Copyright 2012, Integrative Biology.33 (D) Adapted with permission from Boussommier-Calleja
et al., 2018, Copyright 2018, Elsevier.44 (E) Adapted with permission from Lei et al., 2020, Copyright 2017, American Chemical Society.45 (F)
Adapted with permission from Chen et al., 2018, Copyright 2018, National Academy of Sciences.43
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first report showing that lactate can, on its own, initiate
macrophage recruitment and that quercetin, a lactate inhibitor,
can halt this action. Reduced cancer cell migration was
observed for co-cultures with M1 macrophages but not M2.
These findings indicated that M1 macrophages elicit an anti-
metastatic action on tumour cells that is consistent with
clinical results reporting that BCG-induced M1 polarization of
macrophages inhibited progression and metastasis of
transitional cell carcinoma of the bladder (TCCB). Results
indicated that lactate was able to reprogram macrophages from
pro-tumour cells to anti-tumour cells and to reduce cancer cell
viability when in co-culture with macrophages. The quantitative
and dynamic observation of macrophage migration and
behaviour could not have been achieved with conventional
methods, such as tube formatting assays and transwell
migration assays. A similar device was also used for co-
culturing four different cell types to depict a bladder cancer
microenvironment using perfusion equipment to deliver
continuous flow (Fig. 2A).39 The system was composed of a
U-shaped channel with ECM (Matrigel) infused media and cell
culture channels interconnected by microchannels to allow the
different cell types to exchange soluble biological factors and
metabolites. The sensitivity of cancer cells to six different
chemotherapy regimens was assessed to study in vitro the
effects on macrophage migration to the tumour compartment.
The role of nanoparticles (NPs) in immunotherapeutic cell
interactions has also been investigated. Chemokine-loaded
folic-acid conjugated NPs targeting folic-acid receptor
expressing cancer cells were studied in a work by
Wimalachandra et al.46 A device was designed to test the
potential of chemokine-loaded NPs to elicit the migration of
DC and T cells through an endothelial barrier towards cancer
cells. Quantification of DC and T cells showed a greater
presence of these cells after administration of chemokine-
loaded folic-acid NP in comparison to folic-acid NP only.
Alternative device materials have also been used for
immunotherapy studies in microfluidics. A novel microfluidic
device was made of a paper layer containing five
microreactors on top of a PMMA layer with hydrogel
diffusion channels (Fig. 2E).47 The device was developed to
better understand the interactions between cancer and
immune cells involved in tumour escape from immune
surveillance. The chip allowed study of crosstalk between
different cell types which is difficult using traditional Petri-
dishes or well-plates. It can also be used to carry out
neutralising and competitive assays. Paper-based microfluidic
devices are cost-effective and can maintain oxygen and
nutrient gradients that depict organ-level functions.
Immune cell mediated cytotoxicity studies
The most commonly studied form of immunotherapy using
microfluidic technology is ACT therapy (Table 2).
An approach based on impedance sensing and optical
light scattering was used to monitor interaction amongst
tumour, adherent stromal cells and non-adherent immune
cells (Fig. 3E).48 The platform consisted of interdigitated
electrode structures and integrated fully spray-coated organic
photodiode arrays for electrical and optical light scattering
measurements under perfusion conditions. Cellular
impedance sensing was used to detect cell surface
interactions while light scattering was used to determine the
quantity and morphology of cells present, enabling
simultaneous study of tumour cell invasion and escape of
immune surveillance. A few years later, a microfluidic device
was developed for tracking the migration and speed of T cells
through a controlled chemokine gradient,49 showing that
inhibiting the MYCN (N-Myc) proto-oncogene could improve
T cell infiltration. Other work looked at the use of
aminobisphosphonates (N-BPs), such as zoledronic acid (ZA),
as nanoparticle agents to specifically promote anti-tumour
Vδ2 T cell proliferation (Fig. 3B).50 The platform enabled
study of the dynamics of T cell migration through a vascular
bed and across an endothelial monolayer in order to reach
tumour cells embedded in hydrogels.
Models looking at the influence of hypoxia and cytokines
on ACT therapy have also been reported. A microfluidic device
was developed and employed for preclinical assessment of the
toxicity of engineered T cells towards tumour cell aggregates
embedded in a 3D matrix.51 The device was designed for the
evaluation of T cell function against single tumour cells and
aggregates depending on addition of interferon gamma and
TNFα. In this work, outcomes from 3D microfluidic and
standard monolayer assays were compared. The 2D assays
significantly overestimated T cell killing abilities and were
unable to determine an effect of hypoxia on T cell killing.
Whereas the 3D cultures found reduced killing of cancer cells
at 2% O2 compared to 20% O2. Increased killing of cancer
cells was observed in the presence of inflammatory cytokines,
particularly with higher O2 conditions. In a different work,
Ando et al. established a microfluidic protocol integrating an
oxygen gradient to study CAR-T cell behavior under a hypoxic
gradient compared to normoxic conditions (Fig. 3C).52 Results
showed that the highest cytotoxicity occurred in normoxic
conditions with PD-L1 surface expression of T cells increasing
in hypoxic conditions.
In order to determine if monocytes inhibit the function of
engineered T cells (as they do with natural T cells, through
PD-L1/PD-1 signalling), human primary monocytes were used
to mimic the hepatitis B virus (HBV)-related hepatocellular
carcinoma tumour microenvironment (Fig. 3F).55 T cell
cytotoxicity to HepG2 cancer spheroids was found to be
impaired by monocytes for retrovirally transduced T cells
only and not for mRNA electroporated T cells. No such effect
on either T cell type was observed in equivalent 2D assays.
NK cells were also recently investigated with microfluidic
studies. Ayuso et al. designed a multi-chamber microfluidic
device to assess NK cell cytotoxicity and antibody-dependent
cellular cytotoxicity (ADCC).53 NK cells were either embedded
in hydrogel alongside cancer spheroids or perfused through
endothelial channels, so that NK and antibody penetration in
3D and through the vasculature could be observed. Z-Stack
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Table 2 Summary of microfluidic publications concerning immune cell mediated cytotoxicity studies. Legend: Ab: antibody, ADCC: antibody-
dependent cellular cytotoxicity, BCG: Bacillus Calmette–Guérin, CACI-IMPACT: cytotoxicity assay for cancer immunotherapy, CAR-T: chimeric antigen
receptor T cells, CTL: cytotoxic T lymphocytes, DC: dendritic cell, FPR1: frizzled-related protein, EMT: epithelial–mesenchymal transition, HBV: hepatitis
B virus, HUVEC: human umbilical vein endothelial cells, ICB: immune checkpoint blockade, IDES: interdigitated electrode structures, ITO: indium tin
oxide, IT: immunotherapy, OET: optoelectronic tweezers, OPD: organic photodiode, NK: natural killer cells, NP: nanoparticle, PBMC: peripheral blood
mononuclear cells, PC: polycarbonate, PEG-DA: poly(ethylene glycol) diacrylate, PDMS: polydimethylsiloxane, TCR: T cell receptor, TiOPC: titanium
oxide phthalocyanine, ZA: zoledronic acid
Author Topic IT type Model
Chip









Effect of a nonlethal
cytotoxic agent (urine)
on adherent cells in































of T cells through a
chemokine gradient







an array of microchannels
to permit chemical and
physical contact amongst


















an effect of hypoxia





an array of microchannels
to permit chemical and
physical contact amongst

















channel on either side
to represent vasculature.
NK cells either
embedded in the gel or
perfused through the
endothelial channels























































































2316 | Lab Chip, 2021, 21, 2306–2329 This journal is © The Royal Society of Chemistry 2021
Table 2 (continued)
Author Topic IT type Model
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images showed antibodies administered into side channels
were able to extravasate from the endothelial layer and
penetrate the ECM, but not the spheroids. NK cells, however,
were able to home in on tumour spheroids located hundreds
of microns away and to successfully infiltrate and kill tumour
cells on the periphery of a spheroid, as well as in its core.
More recently, the same group adapted the microfluidic set-
up to investigate NK exhaustion due to tumour
environmental stresses reproduced on-a-chip.59 The device
design allowed to control nutrient and pH gradients across
3D tumour models, as well as inducing cell proliferation and
necrosis. Gene expression analysis showed greater exhaustion
of the NK cells cultured in devices in comparison to those in
well plates. However, this effect could be partially negated
with the use of an anti-PD-L1 antibody, atezolizumab, and
IDO-1 inhibitor, epacadostat. Results demonstrated
suppression of NK cell cytotoxicity for regions where MCF7
cells were able to create environmental gradients supportive
of their proliferation. In contrast, patient derived breast
cancer cells were unable to elicit sufficient environmental
stress to be detrimental to NK cell cytotoxicity.
Further, the use of titanium oxide phthalocyanine
(TiOPc)-based optoelectronic tweezers was established for
controlling cell–cell contacts to study immune and cancer
cell interactions (Fig. 3A).54 Single cells were manipulated
into PEG-DA hydrogel four-leaf-clover-shaped microwells,
where direct cell-to-cell contact could occur. The benefit of
this model was that it avoided continuous fluid flow and
shear stress in the specific device regions where secreted
proteins would be washed out and interactions between
cells and NK cell activity were impacted. Park et al.
proposed a 3D cytotoxicity assay to determine cytotoxic
capabilities of lymphocytes (Fig. 3D).56 Polystyrene devices
were mass produced using injection moulding to form
plastic culture arrays and rail-based microstructures with
hydrophilic surfaces. The multi-well format allowed
multiple assays to be performed in one device
simultaneously. Another example of microfluidic
Table 2 (continued)
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immunotherapeutic application to study NK behaviour was
provided by Wu et al. who reported a setup to produce
alginate microspheres to protect NK cells from the TME
and from being rejected by the host's immune system
when injected.57 Microspheres were shown to keep more
than 85% of cells viable after 72 h with cells remaining
viable for up to 14 days. Cytotoxic factors, perforin,
granzyme and IFN-γ were shown to be released from the
cells over a 7 day period. NK cells encapsulated in
microspheres showed greater killing in vivo in comparison
to free NK cells with the microsphere injections not
resulting in any adverse side effects in vivo.
Mechanistic and mode of action studies
Other immunotherapy-related approaches have also been
investigated in microfluidics (Table 3).
A microfluidic platform has been developed and used for
examining the role of macrophages in tumour cell
intravasation.60 Greater tumour cell intravasation and
endothelial permeability was reported when tumour cells
were co-cultured with macrophages. This could be reduced
by administering anti-TNF antibodies. A device originally
used to study angiogenic growth was employed by Jenkins
et al. to test a novel TBK1/IKKε inhibitor on murine-derived
organotypic tumour spheroids (MDOTS) and patient-derived
organotypic tumour spheroids (PDOTS).61 Greater cell death
of MC38 MDOTS was seen when the inhibitor was combined
with anti-PD-1 treatment and was dose- and time-dependent.
The use of plastic microfluidic devices made using cyclic
olefin polymer (COP) have also been proposed by Aref et al. for
testing of immune checkpoint blockade (ICB) in conjunction
with small hydrophobic molecules, as these can be adsorbed
by PDMS.62 Murine- and patient-derived organotypic tumor
spheroids from a patient with a small intestinal
neuroendocrine tumour (SI-NET) were treated with ICB
treatment with anti-PD-1 + anti-CTLA-4 in combination and as
monotherapy. Dual ICB showed greater immune-mediated
killing and relative expansion of CD8 T cells and macrophages
in comparison to control and single agent ICB-treated PDOTS.
Biopsy fragments were also studied in microfluidics developing
an ex vivo immuno-oncology dynamic environment (Fig. 5F).63
This proof-of-concept system allowed culture of up to 12
individual tumour biopsy fragments subjected to flowing
tumour-infiltrating lymphocytes (TIL) in a pressure-pump-
driven system. This set-up was utilised in ICB studies and
Fig. 3 Microfluidic examples of immune cell mediated cytotoxicity. (A) Adapted with permission from Ke et al., 2017, Copyright 2017, Lab on a
Chip.54 (B) Adapted with permission from Di Mascolo et al., 2019, Copyright 2019, Cancers, http://creativecommons.org/licenses/by/4.0/;50 (C)
adapted with permission from Ando et al., 2019, Copyright 2019, Adv. Healthcare Mater.52 (D) Adapted with permission from Park et al., 2019,
Copyright 2019, Frontiers in Immunology, http://creativecommons.org/licenses/by/4.0/.56 (E) Adapted with permission from Charwat et al., 2013,
Copyright 2013, American Chemical Society.48 (F) Adapted with permission from Lee et al., 2018, Copyright 2018, Frontiers in Immunology, http://
creativecommons.org/licenses/by/4.0/.55
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Table 3 Summary of microfluidic publications concerning mechanistic and mode of action studies I/O. Legend: Ab: Antibody, BCG: Bacillus Calmette–
Guérin, CAF: cancer associated fibroblasts, CAR-T: chimeric antigen receptor T cells, COP: cyclo olefin polymer, CTC: circulating tumour cells, DC:
dendritic cell, FPR1: frizzled-related protein, EMT: epithelial–mesenchymal transition, ICB: immune checkpoint blockade, IFNα: interferon alpha, IT:
immunotherapy, MDOTS: murine-derived organotypic tumour spheroids, NK: natural killer cells, NP: nanoparticle, PBMC: peripheral blood mononuclear
cells, PDMS: polydimethylsiloxane, SCC: squamous cell carcinoma, TCR: T cell receptor, TIL: tumour-infiltrating lymphocytes, TME: tumour
microenvironment
Author and ref no. Topic IT type Model
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Table 3 (continued)
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reported increased tumour killing seen in channels with TILs
treated with anti-PD-1 ICI. However, issues with fluid
obstruction due to bubble formation and cell debris
accumulation were recorded.
DC studies have additionally been carried out using
microfluidics. Parlato et al. investigated IFNα-conditioned
dendritic cells for use as a therapeutic vaccine in combinations
with chemotherapy drug, romidepsin.68 Migration channels
connected the tumour and immune chambers to allow analysis
of DC migration, phagocytosis and cell–cell interactions,
aiming to mimic in vivo DC crossing of the endothelial barrier.
A cell electrofusion device that can pair and fuse homogeneous
and heterogeneous cells was produced by Lu et al. and is
relevant to the production of DC-tumour fusion vaccines to
elicit anti-tumour immunity (Fig. 4C).65 The device consisted of
960 pairs of trapping channels with 68% and 64% pairing and
fusion efficiencies, respectively. Fused cells could be easily
extracted from the device, in comparison to other electrofusion
systems. The use of microfluidics in cell fusion offers several
other advantages over conventional methods including: precise
pairing of cells, greater fusion efficiencies and cell viability and
reduced sample contamination and Joule heating effects.
Microfluidic work investigating immunotherapeutic
antibodies has also been reported. Microfluidic assays were
developed controlling cell composition in experiments
carried out with and without the drug, trastuzumab, a
monoclonal antibody against the HER2 receptor (Fig. 4E).70
The device enabled direct visualization and quantification
of proliferation, cell death and motility, including the
influence of co-culture with CAF and immune cells in a 3D
environment. The drug was shown to decrease mitosis,
tumour growth and apoptosis with the extent of these anti-
tumour effects varying depending on the composition of
cells present in the culture. In contrast, 2D experiments
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showed that the drug did not inhibit the growth of these
cancer cells.
Alternative applications for immunotherapy studies
involving microfluidics have included a setup that functioned
to mimic the drug toxicity-induced pulmonary oedema that is
seen in cancer patients after IL-2 treatment (Fig. 4A).69 The
platform hosted alveolar epithelial cells exposed to air flow
and interfaced with an IL-2 perfused endothelial cell
compartment. Cyclic stretching of a flexible membrane
mimicked physiological breathing motions. This device offers
the advantage of a greater level of physiological relevance
than standard static models. Phase contrast microscopy
showed fluid leakage into the alveolar compartment that
gradually reduced the air volume.
Kulasinghe et al. reported a method to identify potential
candidates for PD-L1 therapy.67 This involved a microfluidic
chip with a spiral channel utilizing Dean flows72 (Fig. 4D) to
isolate circulating tumour cells (CTC) from blood of patients
with squamous cell carcinoma. Extracted CTCs where
characterised for PD-L1 expression. Yin et al. established a
dual-antibody-functionalised microfluidic chaotic mixer
using anti-EpCAM and anti-PSMA antibodies immobilized
onto micropillars (Fig. 4B)71 where captured CTCs could be
analysed and subsequently recovered from the device. These
approaches enable valuable tools to enrich CTC samples and
especially offers the potential for personalized therapy by
allowing the identification of the stage of cancer progression
and determination of the optimum course of treatment for
individual patients.
4. Discussion
We have charted the studies reported above according to
aspects that we consider being of particular importance for
broadening the use of microfluidics in immunotherapy
studies: the broad area of immune-oncology investigated or
type of immunotherapy being implemented, the
microfluidic cell model and its complexity, the constituent
material of the microfluidic chip, the type of fluid actuation
used to interface with the microfluidic device and the device
design (Fig. 5).
The majority of these studies focused on investigating
cell-to-cell interactions and cell migration (36%) in a
simplified reconstructed TME, rather than looking at the
effects of specific immunotherapy agents. Of the actual
immunotherapy regimes tested, ACT therapies (33%) were
the most studied, followed by ICB (11%), antibodies (8%), DC
vaccines (6%) and cytokines/chemokines (6%). Immune cell
mediated cytotoxicity has increasingly generated interest in
recent years and has seen success in a range of
haematological malignancies, potentially driving the
development of microfluidic assays in this area. Overall, the
miniaturised environment and the enhanced control over cell
positioning obtained in microfluidics is inherently suitable
Fig. 4 Example of microfluidic technologies for mechanistic and mode of action studies in I/O. (A) Adapted with permission from Huh et al., 2018,
Copyright 2018, Science Translational Medicine.69 (B) Adapted with permission from Yin et al., 2018, Copyright 2018, American Chemical Society.71
(C) Adapted with permission from Lu et al., 2015, Copyright 2015, Oncotarget, http://creativecommons.org/licenses/by/4.0/.65 (D) Adapted with
permission from Warkiani et al., 2014, Copyright 2014, The Royal Society of Chemistry, http://creativecommons.org/licenses/by/4.0/.72 (E) Adapted
with permission from Nguyen et al., 2018, Copyright 2018, The Royal Society of Chemistry, http://creativecommons.org/licenses/by/4.0/.70 (F)
Adapted with permission from Moore et al., 2018, Copyright 2018, The Royal Society of Chemistry.63
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for building advanced complex models that are not easily
achievable with off-chip techniques. Therefore, it is not
surprising that over two thirds of the models implemented
ACT studies and cell-interaction/migration investigation,
these being considerably more challenging to image in vivo
and to recreate in standard well plate systems. One major
advantage of microfluidic models is that these allow for a
reductionist approach by focusing on one area of study and
eliminating other variables. Multiple cell types can be
characterized and their behaviour changes investigated
depending on which cytokines or other cell types are present
in an assay. An open question remains around why other
immunotherapies have not been investigated in microfluidic
formats to date, possibly due to the complexity of the model
required to simulate systemic response when testing vaccines
or non-specific immune-stimulation.
Over a third of the papers considered in this review relied
solely on immortalized cell lines. Over half of the studies
used a combination of primary cells and cell lines, while only
8% used primary tissue alone. Although using primary tissue
increases the complexity of the assays (due to heterogeneity
and potential change in cell phenotype) and the cost, it does
enhance their translational value. As a number of these
studies were proof-of-concept work, it could be argued that
using primary cells would have been an unnecessary
complication, as cell lines guarantee an easier approach to
illustrate the operation of the device and validate the assay
initially. Nonetheless, it is essential that follow-up studies
emerge showing outcomes that go beyond the scope of
proving feasibility of the microfluidic technology alone.
Generally speaking, microfluidic devices are fabricated
using various polymeric materials, from elastomers to
thermoplastics, but also paper and glass as substrates.73
Within the cohort of papers reviewed, the vast majority (80%)
of the devices were fabricated in polydimethylsiloxane
(PDMS), with few reports of thermoplastic, paper and glass
microsystems being used. Soft-lithography is abundantly
used in research laboratories, this involves the fabrication of
microstructures via replica moulding from master templates,
most of which are created by photolithography.74 The most
popular material option for this is PDMS, due to its
favourable bio-chemical properties and lower cost compared
to alternative materials.75 Its optical transparency allows
straightforward visualisation, while its gas permeability
facilitates cell culture.75,76 It can be adjusted to obtain the
desired degree of elasticity, using cross-linking agents.77 The
flexibility of PDMS allows for its use in a wide range of
applications. However, PDMS also presents disadvantages
such as bulk absorption of compounds, especially important
for compound testing,73 and mass production of PDMS based
devices is less straightforward than thermoplastic-based
manufacturing. Glass and silicon microfluidic devices are
more expensive and time consuming to process.78 However,
glass is a durable material and presents less risk of drug
absorption than PDMS.73 Thermoplastics, such as
polycarbonate and polystyrene, can be readily oxidised to
decrease their hydrophobicity for use in microfluidics,79 and
are also better characterized for drug absorption compared to
PDMS, but microfabrication of small features and bonding of
several layers are not straightforward processes compared to
Fig. 5 Characterization of microfluidic approaches for in vitro studies of immunotherapy for solid tumours. Pie charts showing: (A) I/O area or type of
immunotherapy implemented, (B) the origin of the cell used for in vitro assays, (C) the bulk material of the microfluidic device, (D) the type of fluid
actuation, (E) the spatial arrangement of the cell model and (F) the features of the device that characterised or enabled the microfluidic model.
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soft-lithography.73 Overall, the material chosen for the device
has considerable implications for the intended application of
the microfluidic assay. Importantly, interfacing of
microfluidic structures, harbouring 3D cellular models, with
automated imaging techniques and novel image analysis
algorithms can play a fundamental role in large throughput
applications and in the standardization of device features.
The majority of the works under consideration used fluid
actuation equipment, with 61% of the microfluidic devices
relying on manual pipetting alone, whilst 20% were connected
to syringe pumps to achieve flow perfusion. A further 19% of
papers required a multi-equipment system. Syringe, pneumatic,
or peristaltic pumps are commonly used to provide a
controlled, continuous delivery of nutrients to cells via
injection or perfusion using tubing connected to microfluidic
devices. The use of cumbersome, tubing-based external
instrumentation often poses challenges to the development of
the technology for high throughput applications.44
Requirement for automated perfused cell culture is typically
the main driver in deciding whether continuous connection to
external equipment is required. Other solutions are available
that can be implemented with open well-based microfluidics,
such as interfacing with robotic dispensers,80,81 plate rockers82
or bespoke microfluidic layouts that can achieve long-lasting,
self-generated perfusion.83,84
Finally, yet importantly, a predominant structure emerged
regarding the layout of the microfluidic device used,
supporting cell interaction and migration studies.
Individually addressable, parallel multi-chamber designs
(used in ∼70% of the studies, Fig. 5E) allowed initial
compartmentalization of cellular subtypes in adjacent
microenvironments, followed by the development of chemical
and cellular communication across chambers via
microchannel networks or hydrogel barriers. This is possibly
the biggest advantage that the microfluidic mesoscale can
offer with respect to other techniques. It is able to create
complex in vitro multicellular models in 3D in a controlled
manner, enabling steep molecular gradients to be formed,
cell chemotactic mechanisms to be reproduced and different
viscous fluids (i.e. media and hydrogels) to be used
concurrently, recreating several TME characteristics and
offering the possibility to study the interactions between
various immune, stromal and tumour cell types. The
miniaturised scale of microfluidic devices can also provide
opportunities to perform such assays using limited patient
derived samples. However, areas for improvement remain
and the technology requires further development for use in
assays involving a broader range of immunotherapies.
Importantly, many of these studies have also characterised
the discrepancy between performing the same assay in 2D vs.
3D,51,55,56,62 further highlighting how more advanced in vitro
models can be created within the microfluidic environment.
In vitro models are often considered too simplistic in their
depiction of the TME.85 This is certainly the case where 2D,
cost-effective cell monolayers are used.30,86 In vitro 3D models
using ex vivo human tumour tissues,87 such as spheroids and
organoids,88 are increasingly being used, but the immune-
component, vasculature and other stromal components of
such models are often neglected.89,90
The lack of in vitro models that adequately represent the
native in vivo environment remains a significant hurdle in
the preclinical development of immunotherapy.91 In vivo
animal models, can offer greater complexity and a greater
degree of physiological relevance than standard in vitro
models. Various types of murine models are commonly
employed, including immunodeficient (i.e. lack of an intact
immune system) and immunocompetent (i.e. presenting an
intact immune system) mice. Human cancer cell lines and
primary cancer patient tumour tissue can be engrafted into
immunodeficient mice, but these lack adaptive immune cells
and therefore may fail to fully recapitulate immune responses
observed in immunocompetent cancer patients.3 Many
studies have also reported issues with successful engrafting
of human cells and their long-term survival in the host.
While cytokines can be administered in an attempt to
prolong human cell survival in these models, this has the
potential to skew the immune response and could lead to the
acquisition of data that is not representative of the actual
human immune response.92,93 Animal studies are thought to
overestimate the benefit of investigated treatments by
approximately 30%, with less than 8% of in vivo assays able
to be successfully translated into clinical cancer trials.93
These methods also have the disadvantage of the high costs
of experiments, in addition to ethical concerns.94 Advanced
in vitro I/O models could avoid many of the drawbacks of
animal experimentation.
The adoption of microfluidic models into the
pharmaceutical industry could play a significant role during
drug development. Chip-based, advanced and complex
in vitro models can potentially reduce and, in some cases,
replace less predictive 2D assays and more expensive animal
models, providing a scalable and versatile platform for
immunotherapy development.95,96
5. Conclusion and future
opportunities
Overall, microfluidic technologies (including lab-on-a-chip,
organ-on-a-chip and microphysiological systems) have the
potential to offer solutions that can one day outperform current
in vitro and animal models, improving our understanding of I/
O mechanisms and creating predictive and efficient tools for
the cost-effective development of immunotherapies. Looking at
the next 10 years, considerable challenges have to be overcome
to achieve these objectives (Fig. 6).
Most of the studies described in section 3 focussed on
investigating mechanisms of action and represented proof-of-
principle studies related to immunotherapies. Therefore,
further evidence is needed to demonstrate the full potential of
microfluidic assays for testing efficacy of immunotherapies.
Follow-up studies are required that use the technology to drive
the medical or biological investigation, which will in turn
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optimise the technology and define specific applications.
Technology transfer and increased multidisciplinary
collaborations are key aspects to achieve such aims. Alongside
this is the need for funding programmes that can sustain
diverse and large teams working collectively towards the
common goal. Increasing model complexity and data
throughput will require side-by-side advances in the
automation of the microfluidic protocols, as well as in the
development and application of machine learning algorithms
and high-level data interpretation. As well as a broad academic
team, there is a need for collaboration with Pharma industry
and the clinical sector.
It is expected that successful validation of organ-on-a-chip
and microfluidic technologies for a specific immune cell type
will drive its use to study anti-cancer effects on the tumour in
the context of various other immune cells. This will facilitate
mechanistic studies at a lower cost than in vivo animal
experiments, with considerable advantages for straightforward
interfacing to high content imaging equipment. Building upon
the current microfluidic assays developed for ACT therapy and
cell interaction/migration highlighted in this review, we
envisage that the technology can be used to develop new assays
to identify and isolate immune cells from patient derived tissue
and test the efficacy and specificity of T cells (including CAR-T
cells). Additionally, the technology could be used to assess the
efficacy and penetration of oncolytic virus and antibodies into
3D in vitro human models. Finally, the development of body-on-
a-chip platforms, where simplified systemic aspects of the
immune system could be modelled, represent challenging but
rewarding new areas that would benefit those immunotherapies
currently under-investigated in microfluidics experiments.
Miniaturisation makes it feasible for small biopsies to be
used to test multiple therapies in parallel (either using live
micro-fragments or single-cell digested samples), on a scale
not currently possible with macro-size tools. The resulting
increased throughput of information extracted from small
biopsy samples means that more samples can be tested and
more quickly, without the need for long periods of cell
expansion from biopsy cultures. This increases the feasibility
of producing results in a clinically meaningful time-frame for
personalised therapy. Moreover, the use of human clinical
samples is much more likely to identify clinically relevant
mechanisms of resistance than immortalised cell lines or
animal models.97 Together with increased use of human
tissue, there will be a requirement for non-animal derived
hydrogels and supplements to be developed and used, as
cross-species contamination could adversely affect the
predictive value of the assays.
It is expected that over the next few years, the ability of
microfluidic assays to predict clinical outcomes using patient
samples will be assessed initially retrospectively and then
prospectively. This will drive confidence in the technology
and facilitate regulatory approval when using in vitro models.
Increasing success in the development and validation of new
microfluidic I/O assays is expected to drive the integration of
the technology first into routine R&D practise in the
pharmaceutical industry and, subsequently, into clinical care
for precision medicine.
However, limiting factors are currently present that do not
facilitate access to patient samples and collection of clinical
information. New policies should be put in place to
accelerate and simplify access to and sharing of patient
samples and clinical/health data for research at the national
and international levels. This is a key aspect to the faster
development of the technology and its global use in the
biotech industry. Longer term, the use of functional assays
with patient-derived tissue could be a game changer in
selecting effective personalised therapies for patients.
In the past 10 years, there has been an explosion of biotechs
and Pharma investing in new programmes for developing
autologous and allogeneic cell therapies (i.e. Dendreon, Kite,
Novartis, Aivita, Iovance Biotherapeutics, Leucid,
Adaptimmune, Immunocore, Carisma and Allogene to name a
few). However, the majority of associated in vitro tests are
carried out in 2D or using standard well plate technologies
prior to animal models. The miniaturization capabilities
combined with the large data throughput of microfluidic
systems offer a unique opportunity to integrate human tissue-
based advanced assays into industrial preclinical studies for
the development of stratified therapeutic approaches. Since
microfluidics can be used for large-throughput screening,
existing immunotherapies could be tested in combination with
novel agents as part of a combinatorial regime.29,98 The latter
is expected to become a particular area of interest as the effect
of cell therapy can be enhanced when applied in combination
with chemotherapies, radiotherapies or ICIs.99
Fig. 6 Roadmap to success. The path to validate microfluidic technologies for immunotherapy development.
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The landscape depicted in this review shows that in
the field of immunotherapy for solid tumours, the use of
the technology is maturing, but is still in the early stages.
A coordinated effort from a variety of disciplines is
required to widen the field of application, to produce
clinically relevant data and to promote constructive
engagement between developers and end users of new
microfluidic technologies.
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